
|Videos|April 19, 2022
Study Design and Outcomes of the Phase II REFINE Trial
Author(s)Naveen Pemmaraju, MD
A review of the study design and key efficacy and safety outcomes of the REFINE trial studying ruxolitinib plus navitoclax treatment in myelofibrosis.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















